Re: Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm.
作者信息
Guess B, Scholz M
出版信息
J Urol. 2001 May;165(5):1644-5.
PMID:11345950
Abstract
摘要
相似文献
1
2
Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.接受前列腺癌长期药物去势治疗的男性在促黄体生成素释放激素激动剂治疗停止后激素恢复的个体差异。
Scand J Urol Nephrol. 2006;40(3):198-203. doi: 10.1080/00365590600641533.
3
Hormonal treatment of prostate cancer.前列腺癌的激素治疗
N Engl J Med. 1999 Mar 11;340(10):812-3. doi: 10.1056/NEJM199903113401015.
4
Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.基于血清睾酮水平确定促黄体生成素释放激素激动剂的给药间隔：一项前瞻性研究。
J Urol. 2007 Jun;177(6):2132-5; discussion 2135. doi: 10.1016/j.juro.2007.01.157.
5
Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.前列腺癌患者长期使用促黄体生成素释放激素激动剂治疗停止后血清睾酮和促黄体生成素水平的时间进程。
Prostate. 2006 Mar 1;66(4):439-44. doi: 10.1002/pros.20341.
6
Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer.前列腺癌患者长期使用促黄体生成素释放激素激动剂停药后血清睾酮的恢复情况。
Urology. 2008 Jun;71(6):1177-80. doi: 10.1016/j.urology.2007.09.066. Epub 2008 Feb 15.
7
Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm.促黄体生成素释放激素激动剂治疗期间未能达到睾酮去势水平：监测血清睾酮的必要性及治疗决策算法
J Urol. 2000 Sep;164(3 Pt 1):726-9. doi: 10.1097/00005392-200009010-00025.
8
Lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry.黄体生成素释放激素激动剂治疗比手术去势导致的睾酮水平更低：质谱法获得的新见解。
J Urol. 2012 May;187(5):1601-6. doi: 10.1016/j.juro.2011.12.063. Epub 2012 Mar 14.
9
Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer.醋酸环丙孕酮在前列腺癌患者中实现去势及预防促黄体生成素释放激素类似物诱导的睾酮激增方面的有效性。
J Urol. 2005 Jul;174(1):140-2. doi: 10.1097/01.ju.0000161591.86721.e5.
10
Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: insight into mechanisms?促性腺激素释放激素激动剂在注射部位有无无菌性脓肿形成时的失效情况：对机制的深入了解？
Urology. 2006 May;67(5):1084.e15-7. doi: 10.1016/j.urology.2005.11.015.
Zotero 插件